Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 237 publications
Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 08, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2026
Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.
Journal: The oncologist
Published: May 03, 2026
Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.
Journal: Cancers
Published: January 21, 2026
Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy.
Journal: The journal of liquid biopsy
Published: January 13, 2026
Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.
Journal: Cancer
Published: December 11, 2025
Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab.
Journal: Frontiers in oncology
Published: October 08, 2025
Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types".
Journal: Journal for immunotherapy of cancer
Published: June 12, 2025
Last Updated: 09/26/2026